|
1
|
Van Den Eeden SK, Tanner CM, Bernstein AL,
et al: Incidence of Parkinson’s disease: variation by age, gender,
and race/ethnicity. Am J Epidemiol. 157:1015–1022. 2003.
|
|
2
|
Elbaz A, Bower JH, Maraganore DM, et al:
Risk tables for parkinsonism and Parkinson’s disease. J Clin
Epidemiol. 55:25–31. 2002.
|
|
3
|
Dauer W and Przedborski S: Parkinson’s
disease: mechanisms and models. Neuron. 39:889–909. 2003.
|
|
4
|
Mylius V, Engau I, Teepker M, et al: Pain
sensitivity and descending inhibition of pain in Parkinson’s
disease. J Neurol Neurosurg Psychiatry. 80:24–28. 2009.
|
|
5
|
Grachev ID: Dopamine transporter imaging
with [123I]FP-CIT (DaTSCAN) in Parkinson’s disease with depressive
symptoms: a biological marker for causal relationships? J Neurol
Neurosurg Psychiatry. 85:130–131. 2014.
|
|
6
|
Blonder LX, Slevin JT, Kryscio RJ, et al:
Dopaminergic modulation of memory and affective processing in
Parkinson depression. Psychiatry Res. 210:146–149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aarsland D, Zaccai J and Brayne C: A
systematic review of prevalence studies of dementia in Parkinson’s
disease. Mov Disord. 20:1255–1263. 2005.
|
|
8
|
Gan EC, Lau DP and Cheah KL: Stridor in
Parkinson’s disease: a case of ‘dry drowning’? J Laryngol Otol.
124:668–673. 2010.
|
|
9
|
Klebe S, Golmard JL, Nalls MA, et al;
French Parkinson’s Disease Genetics Study Group; International
Parkinson’s Disease Genomics Consortium (IPDGC). The Val158Met COMT
polymorphism is a modifier of the age at onset in Parkinson’s
disease with a sexual dimorphism. J Neurol Neurosurg Psychiatry.
84:666–673. 2013.PubMed/NCBI
|
|
10
|
Rode J, Bentley A and Parkinson C:
Paraganglial cells of urinary bladder and prostate: potential
diagnostic problem. J Clin Pathol. 43:13–16. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Najafi MR, Chitsaz A, Askarian Z and
Najafi MA: Quality of sleep in patients with Parkinson’s disease.
Int J Prev Med. 4(Suppl 2): S229–S233. 2013.
|
|
12
|
Olanow CW and Tatton WG: Etiology and
pathogenesis of Parkinson’s disease. Annu Rev Neurosci. 22:123–144.
1999.
|
|
13
|
Wirdefeldt K, Adami HO, Cole P,
Trichopoulos D and Mandel J: Epidemiology and etiology of
Parkinson’s disease: a review of the evidence. Eur J Epidemiol.
26(Suppl 1): S1–S58. 2011.
|
|
14
|
Vaglini F, Viaggi C, Piro V, et al:
Acetaldehyde and parkinsonism: role of CYP450 2E1. Front Behav
Neurosci. 7:712013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tanner CM, Ottman R, Goldman SM, et al:
Parkinson disease in twins: an etiologic study. JAMA. 281:341–346.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alonso ME, Otero E, D’Regules R and
Figueroa HH: Parkinson’s disease: a genetic study. Can J Neurol
Sci. 13:248–251. 1986.
|
|
17
|
Pankratz N, Nichols WC, Uniacke SK, et al:
Genome-wide linkage analysis and evidence of gene-by-gene
interactions in a sample of 362 multiplex Parkinson disease
families. Hum Mol Genet. 12:2599–2608. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dai D, Wang Y, Wang L, et al:
Polymorphisms of DRD2 and DRD3 genes and Parkinson’s disease: A
meta-analysis. Biomed Rep. 2:275–281. 2014.
|
|
19
|
Corti O, Lesage S and Brice A: What
genetics tells us about the causes and mechanisms of Parkinson’s
disease. Physiol Rev. 91:1161–1218. 2011.PubMed/NCBI
|
|
20
|
Singleton AB, Farrer MJ and Bonifati V:
The genetics of Parkinson’s disease: progress and therapeutic
implications. Mov Disord. 28:14–23. 2013.
|
|
21
|
Cleary SF and Marciano-Cabral F: Soluble
amoebicidal factors mediate cytolysis of Naegleria fowleri
by activated macrophages. Cell Immunol. 101:62–71. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Morrione A: Grb10 adapter protein as
regulator of insulin-like growth factor receptor signaling. J Cell
Physiol. 197:307–311. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dufresne AM and Smith RJ: The adapter
protein GRB10 is an endogenous negative regulator of insulin-like
growth factor signaling. Endocrinology. 146:4399–4409. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Russo VC, Gluckman PD, Feldman EL and
Werther GA: The insulin-like growth factor system and its
pleiotropic functions in brain. Endocr Rev. 26:916–943. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Folli F, Ghidella S, Bonfanti L, Kahn CR
and Merighi A: The early intracellular signaling pathway for the
insulin/insulin-like growth factor receptor family in the mammalian
central nervous system. Mol Neurobiol. 13:155–183. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cardona-Gómez GP, Mendez P, DonCarlos LL,
Azcoitia I and Garcia-Segura LM: Interactions of estrogens and
insulin-like growth factor-I in the brain: implications for
neuroprotection. Brain Res Brain Res Rev. 37:320–334. 2001.
|
|
27
|
Picillo M, Erro R, Santangelo G, et al:
Insulin-like growth factor-1 and progression of motor symptoms in
early, drug-naïve Parkinson’s disease. J Neurol. 260:1724–1730.
2013.PubMed/NCBI
|
|
28
|
Numao A, Suzuki K, Miyamoto M, Miyamoto T
and Hirata K: Clinical correlates of serum insulin-like growth
factor-1 in patients with Parkinson’s disease, multiple system
atrophy and progressive supranuclear palsy. Parkinsonism Relat
Disord. 20:212–216. 2014.
|
|
29
|
Godau J, Knauel K, Weber K, et al: Serum
insulinlike growth factor 1 as possible marker for risk and early
diagnosis of Parkinson disease. Arch Neurol. 68:925–931. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang L, Guo JF, Zhang WW, et al: Follow-up
study of variants of the GIGYF2 gene in Chinese patients with
Parkinson’s disease. J Clin Neurosci. 18:1699–1701. 2011.PubMed/NCBI
|
|
31
|
Dos Santos AV, Pestana CP, Diniz KR, et
al: Mutational analysis of GIGYF2, ATP13A2 and GBA genes in
Brazilian patients with early-onset Parkinson’s disease. Neurosci
Lett. 485:121–124. 2010.PubMed/NCBI
|
|
32
|
Wang L, Guo JF, Zhang WW, et al: Novel
GIGYF2 gene variants in patients with Parkinson’s disease in
Chinese population. Neurosci Lett. 473:131–135. 2010.
|
|
33
|
Guo Y, Jankovic J, Zhu S, et al: GIGYF2
Asn56Ser and Asn457Thr mutations in Parkinson disease patients.
Neurosci Lett. 454:209–211. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li L, Funayama M, Tomiyama H, et al: No
evidence for pathogenic role of GIGYF2 mutation in Parkinson
disease in Japanese patients. Neurosci Lett. 479:245–248. 2010.
View Article : Google Scholar
|
|
35
|
Cao L, Zhang T, Zheng L, et al: The GIGYF2
variants are not associated with Parkinson’s disease in the
mainland Chinese population. Parkinsonism Relat Disord. 16:294–297.
2010.
|
|
36
|
Tan EK, Lin CH, Tai CH, et al:
Non-synonymous GIGYF2 variants in Parkinson’s disease from two
Asian populations. Hum Genet. 126:425–430. 2009.
|
|
37
|
Nichols WC, Kissell DK, Pankratz N, et al;
Parkinson Study Group-PROGENI Investigators. Variation in GIGYF2 is
not associated with Parkinson disease. Neurology. 72:1886–1892.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zimprich A, Schulte C, Reinthaler E, et
al: PARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not
pathogenic for Parkinson’s disease. Parkinsonism Relat Disord.
15:532–534. 2009.PubMed/NCBI
|
|
39
|
Bras J, Simón-Sánchez J, Federoff M, et
al: Lack of replication of association between GIGYF2 variants and
Parkinson disease. Hum Mol Genet. 18:341–346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lautier C, Goldwurm S, Dürr A, et al:
Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in
familial Parkinson disease. Am J Hum Genet. 82:822–833. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bonetti M, Ferraris A, Petracca M,
Bentivoglio AR, Dallapiccola B and Valente EM: GIGYF2 variants are
not associated with Parkinson’s disease in Italy. Mov Disord.
24:1867–1869. 2009.
|
|
42
|
Vilariño-Güell C, Ross OA, Soto AI, et al:
Reported mutations in GIGYF2 are not a common cause of Parkinson’s
disease. Mov Disord. 24:619–620. 2009.
|
|
43
|
Meeus B, Nuytemans K, Crosiers D, et al:
GIGYF2 has no major role in Parkinson genetic etiology in a Belgian
population. Neurobiology Aging. 32:308–312. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yu X, Huang Y, Li C, Yang H, Lu C and Duan
S: Positive association between lymphotoxin-alpha variation
rs909253 and cancer risk: a meta-analysis based on 36 case-control
studies. Tumour Biol. 35:1973–1983. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Huang Y, Yu X, Wang L, et al: Four genetic
polymorphisms of lymphotoxin-alpha gene and cancer risk: a
systematic review and meta-analysis. PLoS One. 8:e825192013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tang L, Wang L, Liao Q, et al: Genetic
associations with diabetes: meta-analyses of 10 candidate
polymorphisms. PLoS One. 8:e703012013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xu X, Wang Y, Wang L, et al: Meta-analyses
of 8 polymorphisms associated with the risk of the Alzheimer’s
disease. PLoS One. 8:e731292013.
|
|
48
|
Excoffier L, Laval G and Schneider S:
Arlequin (version 3.0): an integrated software package for
population genetics data analysis. Evol Bioinform Online. 1:47–50.
2007.
|
|
49
|
Coory MD: Comment on: Heterogeneity in
meta-analysis should be expected and appropriately quantified. Int
J Epidemiol. 39:932–933. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kawalec P, Mikrut A, Wísniewska N and Pilc
A: The effectiveness of tofacitinib, a novel Janus kinase
inhibitor, in the treatment of rheumatoid arthritis: a systematic
review and meta-analysis. Clin Rheumatol. 32:1415–1424. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Giovannone B, Lee E, Laviola L, Giorgino
F, Cleveland KA and Smith RJ: Two novel proteins that are linked to
insulin-like growth factor (IGF-I) receptors by the Grb10 adapter
and modulate IGF-I signaling. J Biol Chem. 278:31564–31573. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Laviola L, Giorgino F, Chow JC, et al: The
adapter protein Grb10 associates preferentially with the insulin
receptor as compared with the IGF-I receptor in mouse fibroblasts.
J Clin Invest. 99:830–837. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mori K, Giovannone B and Smith RJ:
Distinct Grb10 domain requirements for effects on glucose uptake
and insulin signaling. Mol Cell Endocrinol. 230:39–50. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Guella I, Pistocchi A, Asselta R, et al:
Mutational screening and zebrafish functional analysis of GIGYF2 as
a Parkinson-disease gene. Neurobiol Aging. 32:1994–2005. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Gasser T: Genetics of Parkinson’s disease.
J Neurol. 248:833–840. 2001.
|
|
56
|
Sellbach AN, Boyle RS, Silburn PA and
Mellick GD: Parkinson’s disease and family history. Parkinsonism
Relat Disord. 12:399–409. 2006.
|
